INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS...Five Prime Therapeutics Inc • August 23rd, 2013 • Pharmaceutical preparations • California
This Non-Exclusive License Agreement (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Five Prime Therapeutics, Inc. (“FivePrime”) (each a “Party”), a corporation having a principal place of business at 1650 Owens St. Suite 200, San Francisco, CA 94158, is effective on February 1, 2006 (“Effective Date”).
AMENDMENT NO. 1 TO THE LICENSE AGREEMENT EFFECTIVE FEBRUARY 1, 2006 BETWEEN STANFORD UNIVERSITY AND FIVE PRIME THERAPEUTICS INC.Five Prime Therapeutics Inc • August 23rd, 2013 • Pharmaceutical preparations
Effective as of January 22, 2010 (“Amendment Effective Date”), The Board Of Trustees of the Leland Stanford Junior University (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Five Prime Therapeutics, Inc. (“Five Prime”), a company having a primary place of business at 1650 Owens Street, Suite 200, San Francisco, CA 94158, agree to enter into this Amendment No. 1 (“Amendment”) as follows:
ContractLicence Agreement • August 23rd, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Quebec
*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
ContractAmending Agreement • August 23rd, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations
*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
